HC Wainwright Reiterates "Buy" Rating for CG Oncology (NASDAQ:CGON)

HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON - Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $75.00 price target on the stock.

Several other research firms have also recently weighed in on CGON. UBS Group began coverage on CG Oncology in a research report on Thursday, October 24th. They issued a "buy" rating and a $60.00 price objective for the company. Roth Capital upgraded CG Oncology to a "strong-buy" rating in a research note on Tuesday, August 27th. Roth Mkm began coverage on CG Oncology in a research report on Tuesday, August 27th. They set a "buy" rating and a $65.00 price target on the stock. Bank of America reissued a "buy" rating and set a $65.00 price objective on shares of CG Oncology in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada initiated coverage on shares of CG Oncology in a report on Monday, September 23rd. They issued an "outperform" rating and a $66.00 target price on the stock. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $63.88.

CG Oncology Stock Performance

Shares of CGON stock traded down $2.71 during trading hours on Tuesday, hitting $36.98. The company had a trading volume of 525,980 shares, compared to its average volume of 649,111. CG Oncology has a fifty-two week low of $25.77 and a fifty-two week high of $50.23. The company's fifty day moving average is $36.84 and its 200 day moving average is $34.82.

Insider Transactions at CG Oncology

In other news, Director Hong Fang Song sold 650,455 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the transaction, the director now directly owns 586,982 shares in the company, valued at approximately $20,755,683.52. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Trading of CG Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new stake in shares of CG Oncology during the 1st quarter worth approximately $492,000. Vanguard Group Inc. acquired a new position in CG Oncology during the first quarter worth $97,678,000. Ameritas Investment Partners Inc. bought a new position in shares of CG Oncology during the 1st quarter worth approximately $102,000. American International Group Inc. acquired a new stake in CG Oncology during the first quarter worth approximately $13,443,000. Finally, Decheng Capital LLC bought a new stake in CG Oncology during the first quarter worth about $239,642,000. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.